21st February 2017
article written by
Cell Medica

Lead cancer immunotherapy candidate receives FDA fast track designation

Lead cancer immunotherapy candidate receives FDA fast track designation London, UK and Houston, TX, US – February 21, 2017. Cell Medica, a leader in developing cellular immunotherapy for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead oncology product CMD-003 for patients with […]

Read Full Article
10th November 2016
article written by
Cell Medica

Cell Medica and Baylor College of Medicine expand partnership to develop allogeneic CAR-NKT cells for cancer treatment

Cell Medica and Baylor College of Medicine expand partnership to develop allogeneic CAR-NKT cells for cancer treatment London, UK and Houston, TX – November 10, 2016 – Cell Medica, a leader in cellular immunotherapy for cancer, has expanded its partnership with Baylor College of Medicine (‘Baylor’) to develop an off-the-shelf allogeneic cell therapy, taking advantage […]

Read Full Article
24th August 2016
article written by
Cell Medica

Cell Medica and UCL collaborate to develop modified T cell receptor products for the treatment of cancer

Cell Medica and UCL collaborate to develop modified T cell receptor products for the treatment of cancer London, UK – August 24, 2016 – Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and infections, has signed a research collaboration with UCL (University College London) aiming to utilize UCL’s novel T […]

Read Full Article
20th July 2016
article written by
Cell Medica

Lead cancer immunotherapy candidate granted EU orphan drug designations

Lead cancer immunotherapy candidate granted EU orphan drug designations London, UK– July 20, 2016.   Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, has received European Commission orphan drug designations for CMD-003 (baltaleucel-T) as a treatment for extranodal NK/T-cell lymphoma, nasal type, and post-transplant lymphoproliferative disorder. CMD-003 is […]

Read Full Article